A community pharmacist delivered therapeutics outcome monitoring service for hyperlipidemia
|Institution:||University of Sydney|
|Chief Investigator:||Dr Parisa Aslani|
This project aims to develop a new cognitive service in community pharmacy for conducting therapeutic outcomes monitoring in consumers with hyperlipidaemia. In the case of hyperlipidaemia, it has been shown that adherence to therapy has been problematic, and it is thought that the successful implementation of such a service may lead to enhanced medication adherence.
The service will include problem assessment; use of targeted adherence strategies and follow-up. Its impact will be evaluated in terms of changes to adherence and clinical outcomes such as cholesterol levels. A cost effectiveness analysis will be undertaken in which the health consequences of our service will be examined with the costs of providing the service.